Eszter Katona
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
C9orf72 poly(glycine-alanine) knock-in mice exhibit mild rotarod and proteomic changes consistent with amyotrophic lateral sclerosis/frontotemporal dementia.
Journal: Brain communications
Published: June 12, 2025
Correction of dysregulated lipid metabolism normalizes gene expression in oligodendrocytes and prolongs lifespan in female poly-GA C9orf72 mice.
Journal: Nature communications
Published: March 13, 2024
Dual-targeting CRISPR-CasRx reduces C9orf72 ALS/FTD sense and antisense repeat RNAs in vitro and in vivo.
Journal: Nature communications
Published: January 23, 2024
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 06, 2023
Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo.
Journal: Acta neuropathologica communications
Published: March 11, 2023
PolyGR and polyPR knock-in mice reveal a conserved neuroprotective extracellular matrix signature in C9orf72 ALS/FTD neurons.
Journal: Nature neuroscience
Published: February 08, 2023
Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 21, 2021
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
Journal: BMC cancer
Published: January 09, 2021
Using MemBlob to Analyze Transmembrane Regions Based on Cryo-EM Maps.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: February 02, 2020
Last Updated: 09/26/2026